Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion type Assertion NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_head.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion description "[Any drug including anti-TNF ? blocker which can downregulate the TCR, infiltrated neutrophils, or CD163+ macrophages in the synovial tissue is the rationale for the management of SpA.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_provenance.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion evidence source_evidence_literature NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_provenance.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion SIO_000772 23840241 NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_provenance.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion wasDerivedFrom befree-20150227 NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_provenance.
- NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_assertion wasGeneratedBy ECO_0000203 NP747025.RA03WEvvOWfUVs5QFwWPfYhwsxI6MEM9Ws0-Uj3q_IHAc130_provenance.